title: Immediate quantitation of antiarrhythmic drug effect by monophasic action potential recording in coronary artery disease.
abstract: A contact electrode catheter, which permits clinical recording of cardiac monophasic action potentials (MAPs), was used as a means of quantifying the electrophysiologic effect of 2 antiarrhythmic drugs, procainamide and quinidine. MAP recordings were made in continuous fashion from the right ventricle in 16 patients, before and after the intravenous administration of procainamide (11 patients) or quinidine (5). Increases in the MAP duration at 90% repolarization (MAPD90) were used as indexes of drug effect and related to plasma drug level. Surface electrocardiographic (QRS duration, corrected QT interval [QTC]) and electrophysiologic (ventricular effective refractory period) measurements, in addition to MAPD90, were made at the same time as blood sampling for plasma drug level determination. Dose response curves, plotting change in MAPD90 versus plasma drug level, showed strong linear correlation for both procainamide (p less than 0.0001) and quinidine (p less than 0.0001). The variance (error of estimation) of the predictive relation, change in MAPD90 versus plasma drug level, was significantly lower than that of change in QTC (p less than 0.001), QRS duration (p less than 0.0001) or ventricular effective refractory period (p less than 0.0001) versus plasma drug level for both procainamide and quinidine. Changes in MAP duration closely correlate with plasma drug level, and as such, may serve as an immediate, quantitative indicator of myocardial drug effect during the administration of antiarrhythmic agents.
authors: Cardiology Division, Johns Hopkins Medical Institutions, Baltimore, Maryland.
authors: E V
authors: EV
authors: Platia
authors: M L
authors: ML
authors: Weisfeldt
authors: M R
authors: MR
authors: Franz
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D000368:Aged; D006328:Cardiac Catheterization / Q000295:instrumentation; D002304:Cardiac Pacing, Artificial; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D004566:Electrodes; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000097:blood / Q000627:therapeutic use*; D011802:Quinidine / Q000097:blood / Q000627:therapeutic use*; D013610:Tachycardia / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology; D014693:Ventricular Fibrillation / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D011802:Quinidine; D011342:Procainamide